BS_1BWP5MCT
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 19.678055190538764
- age_years
- 4.066
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.582
- E2F_TARGETS+0.430
- MYC_TARGETS_V1+0.369
- G2M_CHECKPOINT+0.362
- SPERMATOGENESIS+0.230
- DNA_REPAIR+0.198
- KRAS_SIGNALING_DN+0.046
- MITOTIC_SPINDLE+0.014
- UNFOLDED_PROTEIN_RESPONSE-0.013
- PEROXISOME-0.103
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.634
- INTERFERON_GAMMA_RESPONSE-0.607
- TNFA_SIGNALING_VIA_NFKB-0.577
- IL6_JAK_STAT3_SIGNALING-0.565
- ALLOGRAFT_REJECTION-0.550
- INFLAMMATORY_RESPONSE-0.549
- COMPLEMENT-0.522
- NOTCH_SIGNALING-0.516
- ANGIOGENESIS-0.510
- APOPTOSIS-0.504
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_D0RDN4K5 | Embryonal tumors | — | 0.978 |
| 2 | BS_3NWQXPQV | medulloblastoma | — | 0.966 |
| 3 | BS_9PB3XH5D | medulloblastoma | — | 0.965 |
| 4 | BS_09Z7TC35 | medulloblastoma | — | 0.964 |
| 5 | BS_V9HVBBDW | medulloblastoma | — | 0.964 |
| 6 | BS_YEB88D32 | medulloblastoma | — | 0.963 |
| 7 | BS_9V633J1X | medulloblastoma | — | 0.962 |
| 8 | BS_W9AT0MR7 | medulloblastoma | — | 0.954 |
| 9 | BS_GE2RVZE6 | medulloblastoma | — | 0.952 |
| 10 | BS_E3BAT4C1 | medulloblastoma | — | 0.951 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.582 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.369 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.362 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.198 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.046 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.014 | Inavolisib | — uncovered |